Three rounds. Six months. Roughly seven times the valuation.
Moonshot AI is in active negotiations for a round of up to $2 billion at a $30 billion post-money target, per Bloomberg reporting confirmed by The Next Web. In December 2025, the company was valued at approximately $4 billion. That’s not a valuation step-up, it’s a sprint.
The round hasn’t closed. Lead investors for this tranche haven’t been named publicly. All financial terms are prospective. That context matters, because the number isn’t a transaction; it’s a negotiating target in a market where targets have been moving fast.
Moonshot AI Valuation Timeline (Per Bloomberg / TNW)
| Date | Event | Reported Valuation | Status |
|---|---|---|---|
| December 2025 | Round 1 | ~$4B | Closed |
| Early 2026 | Round 2 (reportedly Meituan-led) | Reported ~$20B | Closed (unconfirmed) |
| June 2026 (in negotiation) | Round 3 (current) | $30B target | Not closed, in negotiation |
Chinese AI Lab Valuations, Reported Context (Unconfirmed by Primary Sources)
| Company | Reported Valuation | Source Basis | Status |
|---|---|---|---|
| Moonshot AI | $30B (target) | Bloomberg via TNW | In negotiation |
| Zhipu AI | ~$80B (reported) | Bloomberg via TNW, no URL confirmed | Unconfirmed |
| DeepSeek | Up to ~$59B (reported) | Bloomberg via TNW, no URL confirmed | Unconfirmed |
| MiniMax | ~$20B (reported) | Bloomberg via TNW, no URL confirmed | Unconfirmed |
What’s driving it? Moonshot’s Annualized Recurring Revenue topped $200 million as of April 2026. That’s the hard data point behind the valuation story. At a $30 billion target, the implied ARR multiple is roughly 150x, aggressive by any standard, including the standards currently prevailing in the U.S. frontier AI market. The real story is what that multiple signals: Moonshot is pricing on trajectory, not on current revenue scale, and investors are apparently willing to underwrite that bet.
The competitive context is where this gets interesting. Moonshot isn’t alone in this pattern. Chinese AI labs are reportedly capitalizing at a pace that suggests they’re treating the current window as time-limited. Zhipu AI is reportedly valued at approximately $80 billion. DeepSeek is reportedly targeting a valuation of up to $59 billion in its debut external round. MiniMax is reportedly valued at approximately $20 billion. These figures aren’t confirmed by primary sources in available materials, treat them as reported valuations from Bloomberg and TNW, not closed transactions, but the directional picture is consistent. Multiple Chinese labs are simultaneously seeking large external rounds, some for the first time.
The strategic logic behind the sprint isn’t complicated. IPO windows are conditional on market sentiment, regulatory environment, and competitive positioning. Chinese AI labs operating in a market where U.S. export controls on advanced chips create structural constraints have every reason to lock in private capital at favorable terms before public markets open, or before conditions shift. This is the third consecutive month the pipeline has tracked a Chinese AI lab capitalization event at a meaningful scale, following DeepSeek’s reported $4.4 billion external round at a $44 billion valuation in late May.
What to Watch
Moonshot’s Kimi chatbot competes in the consumer and enterprise AI assistant market where scale, response quality, and developer ecosystem are the three leverage points. $200 million ARR demonstrates real commercial traction, not just lab output. But the gap between $200 million ARR and a $30 billion valuation target is large enough that the investment thesis is fundamentally about where the number goes over the next 24-36 months, not where it is today.
Watch the closing terms. If Moonshot closes this round near the $30 billion target, it’ll be the clearest datapoint yet that Chinese AI labs are successfully accessing global capital at valuations that rival U.S. peers at comparable revenue stages. If the round prices lower, or fails to close at the target, that’s a signal about investor conviction in the current Chinese AI lab premium. The Q3 2026 close, or the absence of one, will tell more than the negotiations do.